Lonza to sell capsules & health ingredients business for $3 billion in major strategic shift

FDA nod to groundbreaking combo therapy for relapsed multiple myeloma

This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile

Evogene narrows focus to AI-driven molecule discovery after major strategic overhaul

Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud

Merck delivers resilient 2025 performance despite global headwinds

Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results

Bayer expands MRXperion power injector capabilities with FDA nod

The system also introduces Imaging Scanner Interface 2 (ISI2) capability, enabling direct communication between injector and scanner to improve exam coordination and operational efficiency

Alembic enters US branded market with first sales of Pivya UTI treatment

Pivya is Alembic’s first branded pharmaceutica product in the US and is being marketed through Alembic Therapeutics LLC

NATCO announces launch of Pomalidomide capsules in US

It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma

Moderna strikes $950 million global settlement with Arbutus & Genevant, clears legal hurdles for vaccine pipeline

Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law

Esperion to acquire Corstasis, gaining first FDA-approved nasal spray Diuretic

Glenmark bags FDA nod for generic asthma inhaler with 180-day exclusivity